Key result
Cancer-associated coagulopathy is driven by complex mechanisms including oncogene regulation and tumor-derived tissue factor-positive microparticles, significantly contributing to morbidity and mortality.
Population
Cancer patients at risk of or experiencing thrombohemorrhagic complications
Design
Review
Authors
Loading...
May inform VTE risk stratification in oncology; leaves open translation of mechanistic insights into targeted therapies.
This review provides an updated overview of the mechanisms, risk assessment, and management of cancer-associated coagulopathy and venous thromboembolism.
Falanga et al. (2014) conducted a review in Cancer-associated coagulopathy. Cancer-associated coagulopathy is driven by complex mechanisms including oncogene regulation and tumor-derived tissue factor-positive microparticles, significantly contributing to morbidity and mortality.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: